-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Reiterates Buy on Beta Bionics, Raises Price Target to $32

Benzinga·10/29/2025 14:59:58
Listen to the news
Truist Securities analyst Richard Newitter reiterates Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $28 to $32.